As of May 24, 2025, Biotech Growth Trust PLC has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $704.00, this represents a potential upside of -737.2%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -770.2% |
| Potential Upside (10-year) | -737.2% |
| Discount Rate (WACC) | 8.6% - 10.6% |
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 03-2024 | 80 | 320% |
| 03-2025 | (77) | -197% |
| 03-2026 | (79) | 2% |
| 03-2027 | (84) | 7% |
| 03-2028 | (86) | 2% |
| 03-2029 | (88) | 2% |
| 03-2030 | (89) | 2% |
| 03-2031 | (91) | 2% |
| 03-2032 | (93) | 2% |
| 03-2033 | (95) | 2% |
| 03-2034 | (97) | 2% |
Net profit margin is expected to improve from 94% in 03-2024 to -9200% by 03-2034, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 03-2024 | 75 | 94% |
| 03-2025 | (73) | -7254% |
| 03-2026 | (74) | -7419% |
| 03-2027 | (79) | -7948% |
| 03-2028 | (81) | -8126% |
| 03-2029 | (83) | -8308% |
| 03-2030 | (85) | -8477% |
| 03-2031 | (87) | -8651% |
| 03-2032 | (88) | -8827% |
| 03-2033 | (90) | -9015% |
| 03-2034 | (92) | -9200% |
with a 5-year average of $0 million. Projected CapEx is expected to maintain at approximately 0% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 03-2025 | 0 |
| 03-2026 | 0 |
| 03-2027 | 0 |
| 03-2028 | 0 |
| 03-2029 | 0 |
| 03-2030 | 0 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 0 |
| Days Inventory | 0 |
| Days Payables | 0 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 6M/2025 | (36) | (0) | (0) | 0 | (36) |
| 2026 | (74) | (0) | (0) | 0 | (74) |
| 2027 | (80) | (0) | (0) | 0 | (79) |
| 2028 | (81) | (0) | (0) | 0 | (81) |
| 2029 | (83) | (0) | (0) | 0 | (83) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -770.2% |
| 10-Year DCF (Growth) | 0.00 | -737.2% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Biotech Growth Trust PLC (BIOG.L) a buy or a sell? Biotech Growth Trust PLC is definitely a sell. Based on our DCF analysis, Biotech Growth Trust PLC (BIOG.L) appears to be overvalued with upside potential of -737.2%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $704.00.